



Multiple Sclerosis

Syndicated Thought Leader Insight

Thought Leader Insight & Analysis Report **Multiple Sclerosis Q2 2010**

Therapeutic Class:	CNS Disorders
Focus Area:	Multiple Sclerosis
Specialty/Location:	Neurologists/N. America
Number of Interviews:	6
Number of Pages:	134
Publication Date:	June 2010
Principal Authors:	Tricia L. Hanlon Kim Grant Jeffrey D. Berk, Ph.D., MBA
Product Code:	MAIMQ210-11
Pricing:	\$7,000
Order Info:	www.medpredict.com or call (513) 271-1924

Abstract:

This new Multiple Sclerosis Thought Leader Panel highlights a series of interviews conducted with our experts in June 2010. For this Panel we asked our Thought Leaders to engage in a thought exercise with us. The purpose was to designate their "fantasy formulary," comprised of the top seven therapeutics, currently in the development pipeline, which they want to see available for use in the prevention/treatment of multiple sclerosis. We allowed Panelists to choose the class of drug, a specific drug (if they had a preference), the unmet needs to be addressed and the benefits that they expected their choices to deliver. The Panel's responses are just as enlightening regarding what they would NOT put on their fantasy formularies.

The Panelists discuss a range of topics, including:

- Sequencing therapies,
- Biomarkers,
- Progressive MS,
- Potent immunotherapy,
- Fingolimod / class effects or idiosyncratic,
- Minimally effective orals,
- Neuroregeneration / neurorepair, and
- Other mechanisms (e.g. CTLA4-Ig; inhibition of T-cell costimulation).

Full transcripts of six qualitative interviews with neurologists are included with this report.

MedPredict® Market Research

Telephone: 513.271.1924 – Email: info@medpredict.com – Website: www.medpredict.com
Connecting biopharmaceutical decision-makers with global thought leader insights and perceptions

Drugs/Companies Discussed:

Company	Brand	Compound/Mechanism
Acorda / Elan	Ampyra	dalfampridine; 4-aminopyridine
Bayer-Schering / Genzyme	Campath	alemtuzumab
Biogen Idec		baminercept BG-0012 (fumarate) anti-LINGO
Biogen Idec / Elan	Tysabri	natalizumab
Biogen Idec / Genentech / Roche	Rituxan / MabThera	rituximab ocrelizumab
Biogen / UCB		CDP-323
Boehringer-Ingelheim / Exelixis		S1P1 agonist (preclinical)
Cephalon	Nuvigil	armodafinil
Glycominds	gMS [®] Pro CDMS, gMS [®] Pro EDSS	diagnostics
GSK / Genmab		ofatumumab
Lilly Lilly/Daiichi Sankyo		LY2127399 CS-0777
Merck Serono	Rebif / RNF Mylinax	IFN beta-1a cladribine
Merck Serono / Apitope		ATX-MS-1467
Merck Serono / Lpath	ASONEP	sonepcizumab
Merck Serono / ZymoGenetics		atacept
Novartis Novartis / Kyorin	Gilenia	fingolimod BAF-312
PDL/Biogen/Roche	Zenapax	daclizumab
Roche / Actelion		ACT-S1P1 RA
Sanofi-Aventis		teriflunomide
Teva / Sanofi-Aventis	Copaxone	glatiramer acetate
Teva		laquinimod

Table of Contents

EXECUTIVE SUMMARY 4

Fantasy Formulary - Ground Rules and Scoring	6
--	---

Multiple Sclerosis Fantasy Formulary Results.....	7
---	---

Table 1: Preferred Product Classes (2010)	8
---	---

Table 2: Individual Thought Leader Rankings (2010)	9
--	---

Table 3: Most Frequent Favorably Mentioned Drugs (2010)	11
---	----

REPORT FINDINGS 12

Drug sequencing: Treatment Naive/Treatment Experienced	12
--	----

Biomarkers	13
------------------	----

gMS® Pro CDMS, gMS® Pro EDSS (Glycominds).....	14
--	----

IFN.....	14
----------	----

Disease Activity	15
------------------------	----

Progressive MS.....	16
---------------------	----

Neurorepair / Neuroprotection / Neuroregeneration	17
---	----

anti-LINGO (Biogen Idec)	18
--------------------------------	----

Gene Therapy / siRNA.....	20
---------------------------	----

Mesenchymal Stem Cells	21
------------------------------	----

Cytokines: IL-12/IL-23/p40, IL-17	22
---	----

VLA-4	24
-------------	----

Tysabri; natalizumab (Biogen / Elan)	24
--	----

B-Cell Inhibitors	25
-------------------------	----

CD20	25
------------	----

MabThera / Rituxan (rituximab; Roche / Genentech / Biogen Idec)	25
---	----

Ocrelizumab (Roche / Genentech / Biogen Idec)	29
---	----

Ofatumumab (Genmab / GSK)	31
---------------------------------	----

CXCL-13.....	33
--------------	----

baminercept; BG9924, LTβR-Ig (Biogen)	33
---	----

BAFF /BLyS.....	34
-----------------	----

atacept (ZymoGenetics / Merck Serono)	34
---	----

LY2127399 (Lilly)	35
-------------------------	----

CD52	35
------------	----

Campath; anti-CD-52; alemtuzumab (Genzyme / Bayer-Schering)	35
---	----

Small Molecule Anti-CD52 Modulator	40
--	----

Augment Functional Reserves	41
-----------------------------------	----

Ampyra; dalfampridine (Acorda / Elan)	41
---	----

Nuvigil; armodafinil (Cephalon)	41
---------------------------------------	----

Marginally Effective Oral Disease Modifying.....	43
Immunomodulator	44
teriflunomide (Sanofi-Aventis).....	44
laquinimod (Teva)	47
Panaclar; BG-00012; BG-12; fumarate (Biogen Idec)	48
Oral VLA-4.....	50
CDP323 (UCB / Biogen)	52
Cell Cycle Arrest	53
Mylinax (cladribine; Merck Serono)	53
S1P Receptor Agonists	59
Gilenia; fingolimod (Novartis).....	59
Other S1P Agonists.....	68
Boehringer Ingelheim / Exelixis	69
BAF-312 (KRP-203, Kyorin / Novartis)	69
CS-0777 (Daiichi Sankyo/Lilly)	70
ACT-S1P1 RA (RG3477 Actelion / Roche).....	70
ASONEP (sonepcizumab; LT-1009; Lpath / Merck Serono)	70
Anti-CD-25 (Anti-IL-2)	71
Zenapax (daclizumab; PDL Biopharma/Biogen/Roche)	71
CTLA4-Ig Antagonists.....	72
Orencia; abatacept (Bristol-Myers Squibb).....	72
Vaccine / Therapeutic Peptide.....	74
ATX-MS-1467 (Apitope / Merck Serono).....	74
 THOUGHT-LEADER DISCUSSIONS 75	
 Interview CNS02440	75
Interview CNS02441	84
Interview CNS02442	94
Interview CNS02443	104
Interview CNS02444	114
Interview CNS02445	124

